Key statistics
As of last trade Tiziana Life Sciences Ltd (TLSA:NAQ) traded at 1.14, -34.48% below its 52-week high of 1.74, set on Aug 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.08 |
---|---|
High | 1.17 |
Low | 1.08 |
Bid | 1.14 |
Offer | 1.15 |
Previous close | 1.07 |
Average volume | 156.12k |
---|---|
Shares outstanding | 103.09m |
Free float | 63.74m |
P/E (TTM) | -- |
Market cap | 110.30m USD |
EPS (TTM) | -0.1726 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 16:22 BST.
More ▼
- Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
- Tiziana Life Sciences Appoints New Chief Executive Officer
- Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
- Tiziana Life Sciences Granted FDA Fast Track Designation
- Tiziana Receives $3.4 Million in Non-Dilutive Funding
- Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
- FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
- Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
- Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
- Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
More ▼